Global G-CSF and G-CSF Biosimilars Market Size By Type (Blood Disorders, Oncology Diseases), By Application (Human Growth Hormone, Erythropoietin), By Region, And Segment Forecasts, 2023 to 2032

The Global G-CSF and G-CSF Biosimilars Market was valued at USD 7.1 billion in 2023 and is projected to reach USD 13.4 billion by 2031, growing at a CAGR of 8.3% during the forecast period 2023–2031. Granulocyte Colony-Stimulating Factor (G-CSF) and its biosimilars are increasingly vital in the management of neutropenia associated with chemotherapy, bone marrow transplantation, and other medical treatments. The market’s expansion is driven by the growing prevalence of cancer and chronic illnesses, increasing demand for cost-effective biologics, and continuous innovation in biosimilar manufacturing and approval pathways globally.

Drivers:

1. Rising Prevalence of Cancer and Chemotherapy Procedures:

G-CSF is widely administered to reduce infection risks in cancer patients undergoing chemotherapy. The rising global cancer burden continues to drive demand for both original G-CSF drugs and their biosimilars.

2. Growing Adoption of Biosimilars:

With healthcare systems focusing on affordability and broader patient access, biosimilars offer a cost-effective alternative to branded biologics. Regulatory frameworks in Europe, the U.S., and Asia have facilitated the swift approval and adoption of G-CSF biosimilars.

3. Patent Expirations of Branded Biologics:

The expiry of patents for blockbuster G-CSF brands like Neupogen and Neulasta has opened up lucrative opportunities for biosimilar manufacturers to enter and expand in the market.

Restraints:

1. Regulatory and Manufacturing Complexities:

While biosimilars benefit from simplified pathways, they still face technical barriers in development, testing, and ensuring biosimilarity. This complexity increases time-to-market and compliance costs.

2. Market Competition and Price Erosion:

The influx of biosimilar competitors has led to aggressive pricing strategies, which although beneficial for end-users, poses margin pressures for manufacturers.

Opportunity:

1. Expansion in Emerging Markets:

Countries in Asia-Pacific, Latin America, and the Middle East are rapidly advancing their healthcare infrastructure and biosimilar regulatory policies, creating new growth avenues for G-CSF biosimilar adoption.

2. Technological Advancements in Biopharmaceutical Manufacturing:

Next-generation cell line development, improved purification processes, and the application of AI in biologic development are expected to enhance product quality and production efficiency.

Market by System Type Insights:

By drug type, the Filgrastim segment dominated the market in 2023 due to its widespread clinical use and earlier biosimilar approvals. However, the Pegfilgrastim biosimilars segment is expected to witness the fastest growth during the forecast period, as longer-acting formulations gain popularity for reducing dosing frequency and improving patient compliance.

Market by End-use Insights:

Hospital pharmacies accounted for the largest market share in 2023, benefiting from bulk procurement and institutional usage in oncology wards. Meanwhile, retail pharmacies and specialty clinics are anticipated to gain momentum due to expanding outpatient administration and supportive reimbursement frameworks.

Market by Regional Insights:

North America led the market in 2023, fueled by high cancer incidence, advanced healthcare facilities, and robust regulatory approval for biosimilars. Asia-Pacific is poised to experience the highest CAGR, driven by rising healthcare awareness, favorable government policies, and increasing local biosimilar production in countries like India, China, and South Korea.

Competitive Scenario:

Key market players include Amgen Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sandoz (a Novartis division), Coherus BioSciences, Biocon Biologics, Dr. Reddy’s Laboratories, Mylan N.V. (Viatris), Intas Pharmaceuticals, and Fresenius Kabi. These companies are engaged in partnerships, new biosimilar launches, and expansions in emerging markets to solidify their competitive positioning.

Scope of Work – Global G-CSF and G-CSF Biosimilars Market

Key Market Developments:

March 2024: Biocon Biologics announced the commercial launch of Pegfilgrastim biosimilar in Europe under an exclusive distribution partnership.

October 2023: Coherus BioSciences received FDA approval for its third biosimilar version of Pegfilgrastim aimed at reducing production costs and boosting accessibility.

July 2023: Teva and Alvotech entered a strategic alliance to jointly market new G-CSF biosimilars in the U.S. and European markets.

FAQs:

1. What is the current market size of the Global G-CSF and G-CSF Biosimilars Market?

The market was valued at USD 7.1 billion in 2023.

2. What is the major growth driver of the Global G-CSF and G-CSF Biosimilars Market?

The increasing prevalence of cancer and the cost-effectiveness of biosimilars are key growth drivers.

3. Which is the largest region during the forecast period in the Global G-CSF and G-CSF Biosimilars Market?

North America is the largest region by market share, while Asia-Pacific is the fastest-growing.

4. Which segment accounted for the largest market share in the Global G-CSF and G-CSF Biosimilars Market?

The Filgrastim segment accounted for the largest share in 2023.

5. Who are the key market players in the Global G-CSF and G-CSF Biosimilars Market?

Amgen, Pfizer, Teva, Sandoz, Coherus BioSciences, Biocon, and Mylan (Viatris) are key players.